Trentini Alessandro, Maritati Martina, Rosta Valentina, Cervellati Carlo, Manfrinato Maria Cristina, Hanau Stefania, Greco Pantaleo, Bonaccorsi Gloria, Bellini Tiziana, Contini Carlo
Section of Medical Biochemistry, Molecular Biology and Genetics, Department of Biomedical and Specialist Surgical Sciences, University of Ferrara, Ferrara, Italy.
Section of Dermatology and Infectious Diseases, Department of Medical Sciences, University of Ferrara, Ferrara, Italy.
Front Med (Lausanne). 2020 Sep 8;7:555. doi: 10.3389/fmed.2020.00555. eCollection 2020.
Oxidative stress (OxS) has been linked to several pregnancy-related complications. Previous studies demonstrated that lactoferrin (LF) has the ability to modulate inflammation, OxS and the immune function. Therefore, we aimed to observe whether vaginal LF administration was able to decrease OxS in the amniotic fluid (AF) of pregnant women undergoing mid-trimester genetic amniocentesis. In this open-label clinical study, 60 pregnant women were divided into three groups: CONTROLS ( = 20), not treated with LF; LACTO 4HRS ( = 20), treated with LF 4 h prior to amniocentesis; LACTO 12HRS ( = 20), treated with LF 12 h prior to amniocentesis. Thiobarbituric acid reactive substances (TBARS), total antioxidant status (TAS) and oxidative stress index (OSI) were measured in AF samples. In addition, the antioxidant activity of LF on a cell line was tested. LF decreased the concentration of TBARS in the AF, with LACTO 4HRS demonstrating the lowest value compared with CONTROLS ( < 0.0001). LACTO 4HRS had higher TAS and lower OSI than CONTROLS ( < 0.0001 for both). , LF was effective against the oxidative challenge regardless of the time of pretreatment. In conclusion, LF decreased both and OxS. LF administration may represent an intriguing clinical solution as an adjuvant to treat complications of pregnancy related to inflammation and OxS. Clinicaltrials.gov, NCT02695563. Registered 01 March 2016-Retrospectively registered, https://clinicaltrials.gov/show/NCT02695563.
氧化应激（OxS）与多种妊娠相关并发症有关。先前的研究表明，乳铁蛋白（LF）具有调节炎症、氧化应激和免疫功能的能力。因此，我们旨在观察阴道给予乳铁蛋白是否能够降低接受孕中期遗传羊膜腔穿刺术的孕妇羊水（AF）中的氧化应激。在这项开放标签的临床研究中，60名孕妇被分为三组：对照组（n = 20），未接受乳铁蛋白治疗；LACTO 4HRS组（n = 20），在羊膜腔穿刺术前4小时接受乳铁蛋白治疗；LACTO 12HRS组（n = 20），在羊膜腔穿刺术前12小时接受乳铁蛋白治疗。测定羊水样本中的硫代巴比妥酸反应性物质（TBARS）、总抗氧化状态（TAS）和氧化应激指数（OSI）。此外，还测试了乳铁蛋白对细胞系的抗氧化活性。乳铁蛋白降低了羊水中TBARS的浓度，与对照组相比，LACTO 4HRS组的值最低（P < 0.0001）。LACTO 4HRS组的TAS高于对照组，OSI低于对照组（两者均P < 0.0001）。因此，无论预处理时间如何，乳铁蛋白对氧化应激挑战均有效。总之，乳铁蛋白降低了TBARS和氧化应激。给予乳铁蛋白可能是一种有趣的临床解决方案，作为治疗与炎症和氧化应激相关的妊娠并发症的辅助手段。Clinicaltrials.gov，NCT02695563。于2016年3月1日注册——追溯注册，https://clinicaltrials.gov/show/NCT02695563。
